Clinical Trials Directory

Trials / Completed

CompletedNCT00003916

Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma

Focal Fractionated Conformal Stereotactic Boost Following Conventional Radiotherapy of High Grade Gliomas: A Randomized Phase III Study

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
25 (actual)
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC · Network
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells and may be an effective treatment for patients with glioma. Stereotactic radiation therapy may be able to deliver x-rays directly to the tumor and cause less damage to normal tissue. It is not yet known if standard radiation therapy is more effective when followed by stereotactic radiation therapy. PURPOSE: Randomized phase III trial to compare the effectiveness of standard radiation therapy with or without stereotactic radiation therapy in treating patients who have glioma.

Detailed description

OBJECTIVES: I. Compare the effect of adjuvant conventional radiotherapy with or without fractionated stereotactic boost radiotherapy on survival in patients with high grade glioma. II. Compare the quality of life of these patients after these therapies. OUTLINE: This is a randomized study. Patients are stratified according to WHO disease grade (III vs IV), center, and age (under 40 vs 40 and over). Patients are randomized to undergo stereotactic radiotherapy or no further treatment after conventional radiotherapy. Patients undergo conventional radiotherapy once or twice a day for up to 6 weeks. Patients randomized to receive additional treatment receive stereotactically guided conformal boost radiotherapy for 4 days, within 4 weeks after completion of conventional radiotherapy. Quality of life is assessed before radiotherapy, then at follow up visits. Patients are followed every 3 months for 1 year, every 6 months for 1 year, and then annually thereafter. PROJECTED ACCRUAL: A total of 605 patients will be accrued for this study.

Conditions

Interventions

TypeNameDescription
RADIATIONradiation therapy
RADIATIONstereotactic radiosurgery

Timeline

Start date
1999-04-01
Primary completion
2001-12-01
First posted
2004-02-16
Last updated
2012-09-24

Locations

8 sites across 7 countries: Australia, France, Germany, Netherlands, Spain, Switzerland, United Kingdom

Source: ClinicalTrials.gov record NCT00003916. Inclusion in this directory is not an endorsement.